Key facts
- Pulmocide’s last known valuation is $291.6M (Sep 2025).
- It has raised $267.6M; the latest was Later Stage VC ($28.0M) in Sep 2025.
- Notable investors include F-Prime Capital, Eight Roads, Johnson & Johnson JJDC, SV Health Investors, SR One Capital Management — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Pulmocide
- ·The full record, as it builds
Funding rounds
No funding rounds for Pulmocide are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pulmocide
Developer of antifungal drugs designed to treat acute and chronic respiratory diseases. The company's drugs are specifically designed for inhaled use to maximize the amount of medicine in the lung and spare systemic exposure and are expected to provide superior efficacy against respiratory aspergillosis while minimizing systemic toxicities, optimized for lung delivery and minimal systemic absorption, enabling doctors to provide a safe and effective treatment for their patients
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2007
- Employees
- 28
- Website
- pulmocide.com/
- Ownership
- Privately Held (backing)
Pulmocide doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pulmocide shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pulmocide in its N-PORT filings yet. We sweep new filings monthly.